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Summary
Background: The Lapatinib Expanded Access Program (LEAP) was initiated in 45 countries to provide lapatinib in combination with capecitabine to patients with ErbB2 (HER-2)-positive breast cancer already treated with anthracyclines, taxanes and trastuzumab. We report the results from 12 Central and Eastern European countries. Patients and Methods: By 30 September 2008, 293 patients were enrolled. Patients were monitored for serious adverse events (SAEs) and for any decrease in left ventricular ejection fraction (LVEF). Overall survival and progression-free survival were also assessed. Results: Mean treatment duration was 30 weeks; 107 patients (36.5%) discontinued therapy during the study, mainly due to disease progression (n = 86; 29.4%). A total of 78 SAEs were reported from 47 patients; the most frequently reported was diarrhoea (13 reports). Treatment had a relatively small effect on LVEF. Decreases were minor (0 to < 20%) in 61% of patients at the end of the study. During the study, 3 patients had decreased LVEF meeting the definition of an SAE; these events all resolved. Median overall and median progression-free survival were 37.6 and 21.1 weeks, respectively. Conclusions: Heavily pretreated patients with ErbB2-positive locally advanced or metastatic breast cancer may benefit from treatment with lapatinib and capecitabine, with a low risk of cardiac toxicity.
Introduction
Breastcanceristhemostcommontypeofcancerinwomenin Europe,andindeedworldwide.Despitecontinuousadvances in the diagnosis and treatment of breast cancer, 131,900 womendieofadvancedormetastaticbreastcancerinEurope everyyear,makingup17.5%ofallcancerdeathsinEurope [1] . Central and Eastern Europe (CEE) appears to have slightlylowerincidenceandmortalityratesforbreastcancer thanWesternandNorthernEurope,possiblyduetoadifferent distribution of known risk factors such as postponement or avoidance of childbearing, hormonal contraception, hormonereplacementtherapy,changesinmenstrualhistory,and obesity [2] .
OneofthemostaggressiveformsofbreastcancerisassociatedwiththeoverexpressionoftheErbB2(HER-2)receptor and/oramplificationofthec-erbB2gene.Thisabnormalityis believedtobepresentinabout20%ofbreastcancerpatients [3] ; limited and sometimes anecdotal information suggests a similar proportion of ErbB2-positive patients in individual countriesinCEE.Forexample,arateof14.7%hasbeenre-ported in Slovenia [4] . ErbB2 positivity is associated with poor survival prognosis in untreated breast cancer [5] , and withrelativeresistancetoendocrinetherapyingeneralorto certain types of endocrine therapy or chemotherapy [6, 7] . More recent studies suggest that ErbB2 positivity may be predictiveofadifferentialandsometimesbetterresponseto certainregimens [8, 9] .Untilrecently,theonlytargetedtreatment available specifically for ErbB2-positive breast cancer was the monoclonal antibody trastuzumab. However, many patients still relapse after treatment with trastuzumab; furthermore, its use has been associated with cardiac toxicity [10] .
Lapatinib (Tykerb/Tyverb™, GlaxoSmithKline GmbH & Co KG, Munich, Germany), a small-molecule dual tyrosine kinase inhibitor, targets both ErbB2 and ErbB1 receptors, andappearstohavelowercardiactoxicitythantrastuzumab [11] . The efficacy and safety of lapatinib has been demonstrated in several studies of patients with metastatic breast cancer [12] [13] [14] [15] . Interim analyses of a phase 3 study (EGF100151)oflapatinibincombinationwithcapecitabinein patients with ErbB2-positive and advanced or metastatic breastcancershowedimprovedtimetoprogression,progression-freesurvival(PFS),objectiveresponserate,andclinical benefit rate, without a significant increase in toxicity comparedwithcapecitabinemonotherapy [12, 13] .Thestudywas halted early by the independent data monitoring committee becausesuperiorityontheprimaryendpointoftimetoprogressionwasdemonstratedbythegroupreceivinglapatinibin combinationwithcapecitabine.TheresultsoftheEGF100151 clinicaltrialgenerateddemandforpatientaccesstolapatinib beforemarketingapproval.AglobalLapatinibExpandedAccessProgram(LEAP)wasthereforeinitiatedtoprovidepotentialclinicalbenefittopatientswithErbB2-overexpressing breast cancer, who had previously received anthracyclines, taxanes and trastuzumab, and who were not eligible for another ongoing lapatinib clinical trial. A total of 45 countries worldwide were included in this initiative. The primary purposeofLEAPwastoprovideaccesstolapatinib,butsafety andefficacydatawerealsocollected.Theresultsfortheglobal population involved in LEAP up to 30 September 2008 havebeenreported [16] .Thispaperpresentstheresultsofa subanalysisof293patientsenrolledin12CEEcountriesthat participatedinLEAP.
Patients and Methods
Objectives TheprimaryobjectiveoftheLEAPinitiativewastoofferpre-approval accesstolapatinibincombinationwithcapecitabine,toprovidepotential benefittopatientswithErbB2-overexpressingbreastcancerrefractoryto treatmentwithanthracyclines,taxanesandtrastuzumab.Thesecondary objectivewastoevaluateseriousadverseevents(SAEs)associatedwith thiscombinationtherapyinthispopulationofpatients.
Design
Thiswasasingle-arm,open-label,expanded-accessstudyoflapatinibin combinationwithcapecitabineinpatientswithlocallyadvancedormetastaticbreastcancerwithErbB2-positivetumoursanddiseaseprogression followingpriortreatmentregimenswithanthracycline,taxaneandtrastuzumab.Thestudywasconductedworldwideandwasinitiatedonapercountrybasisincountrieswheretheapplicationforamarketinglicence hadbeensubmitted.
Main Inclusion and Exclusion Criteria
Patients aged ≥ 18 years with locally advanced (stage IIIb or stage IIIc withT4lesion)ormetastatic(stageIV)breastcancerandErbB2-positive tumourswereeligible.Allpatientshadtohavediseaseprogressionfollowing prior therapy with an anthracycline, a taxane and trastuzumab. Patients had to have adequate haematological, hepatic and renal function,leftventricularejectionfraction(LVEF)withintheinstitution'slimit of normal (or > 50%) at baseline, as measured by echocardiogram or multigatedacquisition(MUGA)scans,andalifeexpectancy>8weeks. Patientswithcentralnervoussystemmetastaseswereeligibleiftheydid not require prohibited medications. The protocol was later amended to allow glucocorticoids for neurological signs and symptoms of central nervoussystemmetastases.Priortreatmentwithhormonaltherapy,lapatinib(i.e.aspartofanotherclinicaltrial)orcapecitabine(i.e.asprevious agentoranon-lapatinib-containingregimen)wasalsopermitted.Patients eligible for other ongoing lapatinib clinical trials were not permitted to enrolinLEAP.Allincludedpatientssignedinformedconsentforms.The followingwereexclusioncriteria:pregnancyorlactationatanytimeduringthestudy;anydiseasesignificantlyaffectinggastrointestinalfunction; unresolved or unstable serious toxicity from previous cancer treatment; uncontrolledinfection;inabilitytogiveinformedconsent;oractivecardiac disease. Patients were also excluded if they were receiving concurrentchemotherapy(otherthancapecitabine),radiationtherapy,immunotherapy,biologicaltherapy(includingErbB1and/orErbB2inhibitors),or endocrinetherapy.
Treatment
Patients received lapatinib 1,250 mg/day and capecitabine 2,000 mg/m 2 / day, both orally. Lapatinib was taken at approximately the same time everymorning.Thecapecitabinedosewasdividedandtakenonceinthe morningandonceintheevening,about12hapart,for2weeks,followed Onkologie2011;34:233-238
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Results
Patient Population
LEAPwasimplementedinJune2006.AsLEAPisongoing, theSAEandefficacyanalysesreportedherearebasedonthe data-cut of 30 September 2008. A total of 293 patients with locally advanced or metastatic breast cancer were enrolled from 12 CEE countries ( fig. 1 ). Both the mean and median age of the patients was 52 years, with the age ranging from 22 to 77 years. About a third of the patients (33.6%) had received prior capecitabine therapy (table 1) . The mean durationoflapatinibpluscapecitabinetreatmentinLEAPin CEEwas30weeks,andthemaximumdurationoftreatment was83.9weeks.Atotalof107patients(36.5%)discontinued therapyduringthestudy,themajorityduetodiseaseprogression (n = 86; 29.4%). In addition, 72 patients (24.6%) withdrew from the study, the majority due to death (n = 59; 20.1%) (table 2). There were no reports of accidental overdosesoflapatinib.
bya1-weekdrug-freeperiod.Dosereductionsanddelaysfortoxiceffects duetoeitherdrugwerepermitted.Treatmentwasadministereduntileither disease progression or withdrawal from study due to unacceptable toxicityorotherreasons.
Assessments
Patients were monitored for SAEs; these included any event that was fatal,life-threatening,disablingorincapacitating,resultedinhospitalisation/prolongationofhospitalstay,orwasassociatedwithcongenitalabnormality. SAEs were summarised and categorised by toxicity grade. Treatment toxicity was assessed by clinical and laboratory parameters. Safetyandefficacyassessmentswereperformedevery3and6weeks,respectively, and at the end of treatment. LVEF was evaluated using echocardiograms or MUGA scans, performed at baseline, 6 weeks, 12 weeks, and then at 12-weekly intervals. LVEF (%) was summarised at eachassessment.Boththeabsolutechangefrombaselineandtherelative percentagechangefrombaselineweresummarisedaccordingtothefollowingcategories:anyincrease,0to<20%decrease,≥20%decrease,or ≥20%decreaseandbelowthelowerlimitofnormal.Formonitoringcardiacsafety,theprotocoldefinedadecreaseinLVEF≥20%andbelow theinstitutionallowerlimitofnormal,orNationalCancerInstituteCommon Toxicity Criteria (NCI CTC) grade 3 or 4 left ventricular systolic dysfunction, as an SAEs. Disease progression was determined by the modifiedResponseEvaluationCriteriaInSolidTumors(RECIST) [17] .
Statistics
Noformalhypothesiswastested,astheprimaryobjectivewastomake lapatinib available. However, PFS and overall survival were assessed. Overallsurvivalwasdefinedasthetimefrominitiationofstudymedicationuntildeathduetoanycause.PFSwasdefinedasthetimefrominitiationofstudymedicationuntiltheearliestdateofdiseaseprogressionor deathfromanycause.TheprotocolwasamendedinJune2008toremove thePFSandoverallsurvivalendpointsbecausedatacollectionceasedin countries where the combination received regulatory approval. Therefore,PFSandoverallsurvivalwerecensoredifpatientsdidnothavediseaseprogressionorwerealivebythisdate.
Fig. 1.Number(%)ofpatientsfromcountriesparticipatinginLEAPin
CentralandEasternEurope. 
Interstitial Pneumonitis and Hepatobiliary Events
NopulmonarySAEswerereported.Only3serioushepatobil-iary events were reported, one of which was assessed as possiblyrelatedtolapatinibandcapecitabine.
Safety
Atotalof78SAEswerereportedfrom47patients.Themost frequentlyreportedSAEwasdiarrhoea(13reportsofwhich 11wereassessedasdrug-related).Overall,45%(35/78)ofthe SAEs reported were assessed as related by the investigator. The SAEs reported more than once are shown in table 3. There were 7 reports of SAEs with a fatal outcome, one of which was assessed as possibly related to lapatinib and capecitabineadministrationbutwasalsoconsideredpossibly due to the breast cancer; the remaining 6 fatal events were considerednotrelatedtothestudydrugs.
SAEs of Special Interest Cardiac Safety
Treatment with lapatinib plus capecitabine had a relatively smalleffectonLVEF.MeanLVEFvaluesbyscheduledvisit areshowninfigure2.Inmostpatients(71/116;61%),thedecreasesinLVEFwereminor(0to<20%)attheendofthe study. During the entire study period, only 6/118 patients (5%) experienced a decrease of ≥ 20% in LVEF relative to decrease is in line with previously reported findings with lapatinib. For example, in the study by Cameron et al. [13] (whichwasafollow-upreportofthepivotalstudybyGeyeret al. [12] ), there were no differences in mean LVEF between thecapecitabineandthecapecitabinepluslapatinibgroupsat scheduled assessments. Five patients in the combination group (n = 198) developed decreases in LVEF ≥ 20% and below the institution's limit of normal, but 4 of these were asymptomatic;allhadreturnedtowithinthenormalrangeat follow-upassessment,andlapatinibwasnotdiscontinuedbecauseofadecreaseinLVEFinanypatients.Ameta-analysis of44trialsoflapatinibwith3,689patientsalsoshowedalow incidenceofsymptomaticandasymptomaticLVEFdecrease (0.2and1.4%,respectively) [11] . Otheradverseeventsconsideredpossiblyofparticularimportance were pulmonary toxicity, a known risk associated withErbB1inhibitorssuchasgefitinib [26] ,andhepatobiliary events.TherewerenopulmonarySAEs,andonly3hepato-biliarySAEswerereported,oneofwhichwasassessedaspossiblyrelatedtolapatiniborcapecitabine.
AlthoughaformalhypothesiswasnottestedinLEAP,the efficacyfindingsfromtheCEEcohortweresimilartothose fortheglobalcohortof45countries [16] .Bythecut-offdate, 22.3%ofpatientsintheCEEsubgrouphaddied,compared with29.4%intheglobalcohort.Medianoverallsurvivalwas 37.6weeks(CEE)and39.6weeks(global),andmedianPFS was 21.1 weeks in both the CEE subgroup and the global cohort.IntheEGF100151trial,amongpatientstreatedwith lapatinib plus capecitabine, median overall survival was 67.7 weeks and median time to progression (i.e. time from randomisation to disease progression or death from breast cancer)was27.1weeks [13] .Thesedifferencescouldbedue to patients with poorer prognoses being allowed to enrol in LEAP.Inaddition,incontrasttoEGF100151,LEAPenrolled patientswithpriorcapecitabineexposure.Ofcourse,caution mustbeexercisedincomparingresultsacrossdifferenttrials because differences in the baseline population, prior regimens,treatmentstandardsbycountry,anddifferentstudydesignsmayallaffectstudyoutcomes.Theslightlylessrestrictive inclusion criteria applied in LEAP compared with EGF100151suggestthatthepatientsenrolledinLEAPmay bemoreindicativeofthepatientpopulationactuallytreated ineverydayclinicalpractice.
Conclusion
TheresultsoftheCEEsubgroupanalysisofLEAPconfirm that patients with ErbB2-positive locally advanced or metastaticbreastcancer,whohavebeenpreviouslytreatedwithan anthracycline, a taxane and trastuzumab, may benefit from treatmentwiththecombinationoflapatinibandcapecitabine, withalowriskofcardiactoxicity. 
Discussion
Until recently, trastuzumab was the only targeted treatment available specifically for treating ErbB2-positive breast cancer.However,primaryorsecondaryresistanceoccursinmany patients, and about 50% of patients with metastatic breast cancer treated with trastuzumab progress within 1 year of startingtreatment [18] .Itwasthereforeimportanttodevelop alternative therapies; lapatinib is one such alternative. This reportofaCEEsubgroupofLEAPconfirmsthattreatment with lapatinib and capecitabine may benefit patients whose ErbB2-positive cancer has progressed despite pretreatment with an anthracycline, a taxane and trastuzumab. Other options for treating these patients include continued trastuzumabafterprogression,alone [19] orincombinationwithnew agentssuchasDM1 [20] orpertuzumab [21] ;ornewagentson theirown,forexampleneratinib [22] . FollowingtheresultsoftheEGF100151clinicaltrialwhich showedimprovedPFSofpatientstreatedwithlapatinibplus capecitabine,LEAPwasinitiated.Expandedaccessprograms allow treatments under investigation to be available before regulatoryapproval,particularlyinpatientswhoarelikelyto benefit and who have no other registered treatment options [23] .Inaddition,expandedaccessprogramsmayallowtheinclusionofpatientswhoarenoteligibleforclinicaltrials,and thusprovideimportantsafetyinformation. Thegoodsafetyprofileoflapatinibfoundinthissubgroup of CEE patients was consistent with the results of previous clinicalstudies [24, 25] .IntheCEEcohortofLEAP,45%of SAEswereconsideredaspossiblyrelatedtothestudydrug; theproportionwasslightlylowerintheglobalLEAPresults (38%) [16] . As in other studies of lapatinib, including the pivotalstudybyGeyeretal. [12] ,themostpronouncedSAE, inboththeglobalandCEEpopulations,wasdiarrhoea.
Cardiactoxicityisawell-knownriskassociatedwithtrastuzumab [10] ;cardiacfunctionisthereforecloselymonitoredin clinicaltrialswithanti-ErbB2agents.Inthissubgroupanalysis of CEE countries enrolled in LEAP, as in the global cohort,treatmentwithlapatinibpluscapecitabineappearedto havelittleeffectonmeanLVEF.IntheCEEsubgroup,3/293 patients(1.0%)hadadecreasedLVEFthatmettheprotocolspecified serious definition, compared with 21/4,283 patients (0.5%) in the global cohort. This low incidence of LVEF
